Cutting-Edge Maternal Health Technologies to Address Postpartum Hemorrhage and Preeclampsia/Eclampsia




Session Date: April 22, 2021

Session Description: The Devices, Diagnostics, and Drugs to Address Women’s Needs Product Development Partnership (D3AWN PDP), funded through UKAID, is addressing the leading causes of maternal mortality by advancing a portfolio of four products designed to be affordable, accessible, safe, and effective options for prevention and management of postpartum hemorrhage (PPH) and preeclampsia/eclampsia (PE/E) in African markets. Our portfolio of innovative technologies includes the: •Ellavi uterine balloon tamponade for the management of refractory PPH •Protein-to-creatinine ratiometric diagnostic strip test for improved diagnoses of PE/E across routine antenatal care settings •RELI Delivery System, a reusable, low-power, infusion pump for lifesaving drug therapies •Sublingual oxytocin in heat-stable fast-dissolving tablets for PPH prevention and/or management These lifesaving technologies are being developed using a human-centered design approach and in partnership with ministries of health, research institutions, manufacturers, and companies in Africa, accelerated through PATH’s product development process and deep expertise with public-private partnerships, and introduced into key African markets. This session will utilize participant polls, video, virtual product demonstrations and PowerPoint presentations to showcase how the four technologies that are in various stages of product development could be used to strengthen the postpartum hemorrhage and preeclampsia/eclampsia continuum of care.